Table 3.

Distribution of patients respect to concordance/discordance between mutational status detection at T0 and T1 and between therapy response evaluation

Mutational status on T0 and T1	n	PD	SD	12-month PFS (95% CI)	12-month OS (95% CI)
Mutation at T0–mutation at T1	9	9	0	22.2% (6.5–75.4%)	55.6 (20.4–96.1%)
Mutation at T0–no mutation at T1	4	1	3	50.0% (18.8–100%)	75.0% (12.8–96.1%)
No mutation at T0–no mutation at T1	6*	2	4	66.7% (27.2–100%)	100% (1.00–1.00)

PD progressive disease, SD stable disease, PFS progression-free survival, OS Overall survival

*5 are included in the survival analysis: one patient excluded because of progressive disease prior to EGFR-TKI treatment and received first-line therapy